{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:11:58Z","timestamp":1784970718472,"version":"3.55.0"},"reference-count":27,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Alzheimer\u2019s disease affects millions of people worldwide, and very few\ndrugs are available for its treatment. Monoclonal antibodies have shown promising effects in the\ntreatment of various types of diseases. Bapineuzumab is one of the humanized monoclonal antibodies,\nwhich have shown promising effects in AD patients. Bapineuzumab has shown efficacy in\nthe treatment of mild to moderate Alzheimer\u2019s disease. However, its safety is still unclear.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Thus, the main objective of the current study is to find out the exact safety profile of\nbapineuzumab in the treatment of mild to moderate Alzheimer\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We performed a web-based literature search of PubMed and clinical trial websites using\nthe relevant keywords. Data were extracted from eligible records, and the risk ratio (RR) was calculated\nwith a 95% confidence interval (CI). All the analyses were performed using Review Manager\nsoftware (version 5.3 for windows). Heterogeneity was measured by Chi-square and I-square\ntests.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Non-significant association of bapineuzumab with serious treatment-emergent adverse\nevents [RR: 1.11 (0.92, 1.35)], headache [RR: 1.03 (0.81, 1.32)], delirium [RR: 2.21 (0.36, 13.53)],\nvomiting [RR: 0.92 (0.55, 1.55)], hypertension [RR: 0.49 (0.12, 2.12)], convulsions [RR:2.23\n(0.42, 11.71)], falls [RR: 0.98 (0.80, 1.21)], fatal AEs [RR: 1.18 (0.59, 2.39)], and neoplasms\n[RR:1.81 (0.07, 49.52)] was reported; however, a significant association was found with vasogenic\nedema [RR: 22.58 (3.48, 146.44)].<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Based on available evidence, bapineuzumab is found to be safe in the treatment of\nAD patients. However, vasogenic edema should be considered.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207326666230419095813","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T04:18:32Z","timestamp":1681964312000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety Analysis of Bapineuzumab in the Treatment of Mild to Moderate Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.2174","volume":"27","author":[{"given":"Yaqi","family":"Gao","sequence":"first","affiliation":[{"name":"College of Nursing, Hebi Polytechnic, Hebi, Henan, 458030 China"},{"name":"College of Health Care, Sehan University,\nYeongam-gun, 58447, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[{"name":"College of Nursing, Hebi Polytechnic, Hebi, Henan, 458030 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Nursing, Hebi Polytechnic, Hebi, Henan, 458030 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Li","sequence":"additional","affiliation":[{"name":"College of Nursing, Hebi Polytechnic, Hebi, Henan, 458030 China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.1132814","volume":"314","author":"Goedert M.","year":"2006","unstructured":"Goedert M.; Spillantini M.G.; A century of Alzheimer\u2019s disease. Science 2006,314(5800),777-781","journal-title":"Science"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"Karch C.M.","year":"2015","unstructured":"Karch C.M.; Goate A.M.; Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015,77(1),43-51","journal-title":"Biol Psychiatry"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bios.2016.05.066","volume":"85","author":"Xia N.","year":"2016","unstructured":"Xia N.; Zhou B.; Huang N.; Jiang M.; Zhang J.; Liu L.; Visual and fluorescent assays for selective detection of beta-amyloid oligomers based on the inner filter effect of gold nanoparticles on the fluorescence of CdTe quantum dots. Biosens Bioelectron 2016,85,625-632","journal-title":"Biosens Bioelectron"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"Nelson P.T.","year":"2012","unstructured":"Nelson P.T.; Alafuzoff I.; Bigio E.H.; Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012,71,362-381","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"Thies W.","year":"2013","unstructured":"Thies W.; Bleiler L.; 2013 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2013,9(2),208-245","journal-title":"Alzheimers Dement"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrd2314","volume":"6","author":"Melnikova I.","year":"2007","unstructured":"Melnikova I.; Therapies for Alzheimer\u2019s disease. Nat Rev Drug Discov 2007,6(5),341-342","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/biomedicines9111689","volume":"9","author":"Moreta M.P.G.","year":"2021","unstructured":"Moreta M.P.G.; Burgos-Alonso N.; Torrecilla M.; Marco-Contelles J.; Bruzos-Cid&#xF3;n C.; Efficacy of acetylcholinesterase inhibitors on cognitive function in Alzheimer\u2019s disease. Review of reviews. Biomedicines 2021,9(11),1689","journal-title":"Biomedicines"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00000441-200207000-00004","volume":"324","author":"Berger M.","year":"2002","unstructured":"Berger M.; Shankar V.; Vafai A.; Therapeutic applications of monoclonal antibodies. Am J Med Sci 2002,324(1),14-30","journal-title":"Am J Med Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/alzrt272","volume":"6","author":"Goure W.F.","year":"2014","unstructured":"Goure W.F.; Krafft G.A.; Jerecic J.; Hefti F.; Targeting the proper amyloid-beta neuronal toxins: A path forward for Alzheimer\u2019s disease immunotherapeutics. Alzheimers Res Ther 2014,6(4),42","journal-title":"Alzheimers Res Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"Bard F.","year":"2000","unstructured":"Bard F.; Cannon C.; Barbour R.; Burke R.L.; Games D.; Grajeda H.; Guido T.; Hu K.; Huang J.; Johnson-Wood K.; Khan K.; Kholodenko D.; Lee M.; Lieberburg I.; Motter R.; Nguyen M.; Soriano F.; Vasquez N.; Weiss K.; Welch B.; Seubert P.; Schenk D.; Yednock T.; Peripherally administered antibodies against amyloid &#x3B2;-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000,6(8),916-919","journal-title":"Nat Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"Bard F.","year":"2003","unstructured":"Bard F.; Barbour R.; Cannon C.; Carretto R.; Fox M.; Games D.; Guido T.; Hoenow K.; Hu K.; Johnson-Wood K.; Khan K.; Kholodenko D.; Lee C.; Lee M.; Motter R.; Nguyen M.; Reed A.; Schenk D.; Tang P.; Vasquez N.; Seubert P.; Yednock T.; Epitope and isotype specificities of antibodies to &#x3B2;-amyloid peptide for protection against Alzheimer\u2019s disease-like neuropathology. Proc Natl Acad Sci 2003,100(4),2023-2028","journal-title":"Proc Natl Acad Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1523\/JNEUROSCI.1697-05.2005","volume":"25","author":"Buttini M.","year":"2005","unstructured":"Buttini M.; Masliah E.; Barbour R.; Grajeda H.; Motter R.; Johnson-Wood K.; Khan K.; Seubert P.; Freedman S.; Schenk D.; Games D.; &#x3B2;-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer\u2019s disease. J Neurosci 2005,25(40),9096-9101","journal-title":"J Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"Shankar G.M.","year":"2008","unstructured":"Shankar G.M.; Li S.; Mehta T.H.; Garcia-Munoz A.; Shepardson N.E.; Smith I.; Brett F.M.; Farrell M.A.; Rowan M.J.; Lemere C.A.; Regan C.M.; Walsh D.M.; Sabatini B.L.; Selkoe D.J.; Amyloid-&#x3B2; protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med 2008,14(8),837-842","journal-title":"Nat Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1523\/JNEUROSCI.1676-11.2012","volume":"32","author":"Zago W.","year":"2012","unstructured":"Zago W.; Buttini M.; Comery T.A.; Nishioka C.; Gardai S.J.; Seubert P.; Games D.; Bard F.; Schenk D.; Kinney G.G.; Neutralization of soluble, synaptotoxic amyloid &#x3B2; species by antibodies is epitope specific. J Neurosci 2012,32(8),2696-2702","journal-title":"J Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"Salloway S.","year":"2009","unstructured":"Salloway S.; Sperling R.; Gilman S.; Fox N.C.; Blennow K.; Raskind M.; Sabbagh M.; Honig L.S.; Doody R.; van Dyck C.H.; Mulnard R.; Barakos J.; Gregg K.M.; Liu E.; Lieberburg I.; Schenk D.; Black R.; Grundman M.; A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009,73(24),2061-2070","journal-title":"Neurology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"Rinne J.O.","year":"2010","unstructured":"Rinne J.O.; Brooks D.J.; Rossor M.N.; Fox N.C.; Bullock R.; Klunk W.E.; Mathis C.A.; Blennow K.; Barakos J.; Okello A.A.; de LIano, S.R.M.; Liu, E.; Koller, M.; Gregg, K.M.; Schenk, D.; Black, R.; Grundman, M. 11C-PiB PET assessment of change in fibrillar amyloid-&#x3B2; load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010,9(4),363-372","journal-title":"Lancet Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","volume":"24","author":"Black R.S.","year":"2010","unstructured":"Black R.S.; Sperling R.A.; Safirstein B.; Motter R.N.; Pallay A.; Nichols A.; Grundman M.; A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010,24(2),198-203","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"Salloway S.","year":"2014","unstructured":"Salloway S.; Sperling R.; Fox N.C.; Blennow K.; Klunk W.; Raskind M.; Sabbagh M.; Honig L.S.; Porsteinsson A.P.; Ferris S.; Reichert M.; Ketter N.; Nejadnik B.; Guenzler V.; Miloslavsky M.; Wang D.; Lu Y.; Lull J.; Tudor I.C.; Liu E.; Grundman M.; Yuen E.; Black R.; Brashear H.R.; Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 2014,370(4),322-333","journal-title":"N Engl J Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/ggi.12516","volume":"16","author":"Arai H.","year":"2016","unstructured":"Arai H.; Umemura K.; Ichimiya Y.; Iseki E.; Eto K.; Miyakawa K.; Kirino E.; Shibata N.; Baba H.; Tsuchiwata S.; Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer\u2019s disease. Geriatr Gerontol Int 2016,16(5),644-650","journal-title":"Geriatr Gerontol Int"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"Page M.J.","year":"2021","unstructured":"Page M.J.; McKenzie J.E.; Bossuyt P.M.; Boutron I.; Hoffmann T.C.; Mulrow C.D.; Shamseer L.; Tetzlaff J.M.; Akl E.A.; Brennan S.E.; Chou R.; Glanville J.; Grimshaw J.M.; Hr&#xF3;bjartsson A.; Lalu M.M.; Li T.; Loder E.W.; Mayo-Wilson E.; McDonald S.; McGuinness L.A.; Stewart L.A.; Thomas J.; Tricco A.C.; Welch V.A.; Whiting P.; Moher D.; The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021,372(71),n71","journal-title":"BMJ"},{"key":"ref=21","unstructured":"Institute of Medicine (US) Council on Health Care Technology; Goodman C, editor. Medical Technology Assessment Directory: A Pilot Reference To Organizations, Assessments, and Information Resources. Washington (DC): National Academies Press (US); 1988. National Heart, Lung, and Blood Institute. Available from:"},{"key":"ref=22","year":"2021","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4.  Accessed on 22 May 20222021"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1517\/14712598.2010.493872","volume":"10","author":"Kerchner G.A.","year":"2010","unstructured":"Kerchner G.A.; Boxer A.L.; Bapineuzumab. Expert Opin Biol Ther 2010,10(7),1121-1130","journal-title":"Expert Opin Biol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12883-017-0850-1","volume":"17","author":"Abushouk A.I.","year":"2017","unstructured":"Abushouk A.I.; Elmaraezy A.; Aglan A.; Salama R.; Fouda S.; Fouda R.; AlSafadi A.M.; Bapineuzumab for mild to moderate Alzheimer\u2019s disease: A meta-analysis of randomized controlled trials. BMC Neurol 2017,17(1),66","journal-title":"BMC Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/jnnp-2020-323497","volume":"91","author":"Lu L.","year":"2020","unstructured":"Lu L.; Zheng X.; Wang S.; Tang C.; Zhang Y.; Yao G.; Zeng J.; Ge S.; Wen H.; Xu M.; Guyatt G.; Xu N.; Anti-A&#x3B2; agents for mild to moderate Alzheimer\u2019s disease: Systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2020,91(12),1316-1324","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e14515","DOI":"10.1111\/ijcp.14515","volume":"75","author":"Srivastava R.","year":"2021","unstructured":"Srivastava R.; Kumar A.; Use of aspirin in reduction of mortality of COVID\u201019 patients: A meta\u2010analysis. Int J Clin Pract 2021,75(11),e14515","journal-title":"Int J Clin Pract"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1021\/acschemneuro.1c00353","volume":"12","year":"2021","unstructured":"D, V.; Sharma, A.; Kumar, A.; Flora, S.J.S. Neurological manifestations in COVID-19 patients: A meta-analysis. ACS Chem Neurosci 2021,12(15),2776-2797","journal-title":"ACS Chem Neurosci"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207326666230419095813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216038\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207326666230419095813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T11:35:06Z","timestamp":1705059306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216038\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207326666230419095813","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}